DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide with a unique mechanism — rather than acting as a sedative, it appears to normalize and optimize sleep architecture, particularly promoting the restorative delta (slow-wave) sleep phase.
Research Applications
Sleep architecture research, stress response modulation, cortisol regulation, chronic pain studies, and withdrawal management models.
Dosage Information (Research Use)
Research protocols: 100-300 mcg subcutaneously or IV, typically administered in the evening. Course-based protocols (10-14 days) documented in European clinical research. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Short plasma half-life (minutes), but sleep-modulating effects persist for hours, suggesting downstream neuromodulatory cascades.
Reported Observations in Literature
Generally well-tolerated. Does not produce next-day sedation or cognitive impairment. No dependence or tolerance reported in available literature.
Key Research References
- Schoenenberger GA, Monnier M. “Characterization of a delta-electroencephalogram-sleep-inducing peptide.” Proc Natl Acad Sci USA. 1977